946582-61-2

Usage

Uses

Used in Organic Synthesis:
(2,3-difluoro-5-nitrophenyl)methanol is used as a building block for the synthesis of various pharmaceutical and agrochemical products due to its versatile structure containing both fluorine and nitro groups.
Used in Pharmaceutical Research:
(2,3-difluoro-5-nitrophenyl)methanol is used as a reagent in the preparation of other compounds and as a starting material for the synthesis of new molecules with potential biological activity, contributing to the discovery and development of novel therapeutic agents.
Used in Chemical Research and Development:
(2,3-difluoro-5-nitrophenyl)methanol is used as a valuable tool for chemical research and development, enabling the exploration of new synthetic pathways and the creation of innovative molecules with potential applications in various fields.

Upstream product

• 942035-31-6 2,3-difluoro-5-nitrobenzoic acid 

Downstream Products

• 1415250-03-1 (5-amino-2,3-difluorophenyl)methanol 
• 946582-63-4 (3-fluoro-2-(methylamino)-5-nitrophenyl)methanol 

Relevant academic research and scientific papers

Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer

Selective inhibition of exclusively transcription-regulating positive transcription elongation factor b/CDK9 is a promising new approach in cancer therapy. Starting from atuveciclib, the first selective CDK9 inhibitor to enter clinical development, lead optimization efforts aimed at identifying intravenously (iv) applicable CDK9 inhibitors with an improved therapeutic index led to the discovery of the highly potent and selective clinical candidate VIP152. The evaluation of various scaffold hops was instrumental in the identification of VIP152, which is characterized by the underexplored benzyl sulfoximine group. VIP152 exhibited the best preclinical overall profile in vitro and in vivo, including high efficacy and good tolerability in xenograft models in mice and rats upon once weekly iv administration. VIP152 has entered clinical trials for the treatment of cancer with promising longterm, durable monotherapy activity in double-hit diffuse large B-cell lymphoma patients.

DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP

The present invention relates to disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of diso

4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES CONTAINING A SULFOXIMINE GROUP

The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).

BENZOXAZINONE AND BENZOXAZEPINONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS

The present invention provides a compound of formula (I) wherein X is a structure of the following formula (i), (ii), (iii), or iv G is O, or S; U is -(CR3R4)n-; W is CH2NHC(=G)R1, CH2NH-het, CH2-G-het, CH2het, C(=O)NHR2; and Y1, Y2 and Y3 are independently CH, or CF. The compounds of the present invention are useful as antibacterial agents.